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Abstract. 
 
Transforming growth factor-
 
b
 
 (TGF-
 
b
 
) is se-
creted by many cell types as part of a large latent com-
plex composed of three subunits: TGF-
 
b
 
, the TGF-
 
b
 
 
propeptide, and the latent TGF-
 
b
 
 binding protein 
(LTBP). To interact with its cell surface receptors, 
TGF-
 
b
 
 must be released from the latent complex by 
disrupting noncovalent interactions between mature 
TGF-
 
b
 
 and its propeptide. Previously, we identified 
LTBP-1 and transglutaminase, a cross-linking enzyme, 
as reactants involved in the formation of TGF-
 
b
 
. In this 
study, we demonstrate that LTBP-1 and large latent 
complex are substrates for transglutaminase. Further-
more, we show that the covalent association between 
LTBP-1 and the extracellular matrix is transglutami-
nase dependent, as little LTBP-1 is recovered from ma-
trix digests prepared from cultures treated with trans-
glutaminase inhibitors. Three polyclonal antisera to 
glutathione S–transferase fusion proteins containing 
amino, middle, or carboxyl regions of LTBP-1S were 
used to identify domains of LTBP-1 involved in cross-
linking and formation of TGF-
 
b
 
 by transglutaminase. 
Antibodies to the amino and carboxyl regions of 
LTBP-1S abrogate TGF-
 
b
 
 generation by vascular cell 
cocultures or macrophages. However, only antibodies 
to the amino-terminal region of LTBP-1 block trans-
glutaminase-dependent cross-linking of large latent 
complex or LTBP-1. To further identify transglutami-
nase-reactive domains within the amino-terminal re-
gion of LTBP-1S, mutants of LTBP-1S with deletions 
of either the amino-terminal 293 (
 
D
 
N293) or 441 
(
 
D
 
N441) amino acids were expressed transiently in 
CHO cells. Analysis of the LTBP-1S content in matri-
ces of transfected CHO cultures revealed that 
 
D
 
N293 
LTBP-1S was matrix associated via a transglutaminase-
dependent reaction, whereas 
 
D
 
N441 LTBP-1S was not. 
This suggests that residues 294–441 are critical to the 
transglutaminase reactivity of LTBP-1S.
 
M
 
ost
 
 cell types secrete transforming growth fac-
tor-
 
b
 
1 (TGF-
 
b
 
)
 
1
 
 in a biologically inactive form
(42). Mature TGF-
 
b
 
 is a homodimer composed
of two 12.5-kD polypeptides joined by a disulfide bond at
cysteine 77 (14). The monomeric subunits are produced by
intercellular cleavage of a higher mol wt precursor at a
dibasic site immediately preceding Ala-279 (17, 21). How-
ever, after secretion the propeptides remain associated
with TGF-
 
b
 
 through noncovalent interactions, rendering
TGF-
 
b
 
 inactive (20). TGF-
 
b 
 
with its propeptide, also known
as the latency associated peptide (LAP), is referred to as
the small latent complex. Both in vitro and in vivo, latent
TGF-
 
b
 
 is secreted as part of a large latent complex in
which a second gene product, the latent TGF-
 
b
 
 binding
protein (LTBP), is disulfide-linked to LAP (42). The dis-
sociation of TGF-
 
b
 
 from LAP is required for TGF-
 
b
 
 to
bind to its receptors and exert its effects on cell prolifera-
tion, extracellular matrix (ECM) deposition, cell migra-
tion, and differentiation (34, 38, 58). Latent TGF-
 
b
 
 is acti-
vated by heat, acid or alkaline treatment, binding to
thrombospondin, deglycosylation, proteolysis, or irradia-
tion (5, 9, 34, 35, 56). The most extensively studied process
for activating large latent complex is a plasmin-dependent
mechanism observed in several tissue culture systems in-
cluding bovine aortic endothelial (BAE) cells treated with
retinoids, cocultures of endothelial cells and either smooth
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1. 
 
Abbreviations used in this paper
 
: BAE, bovine aortic endothelial; BSM,
bovine smooth muscle; CM, conditioned medium; ECM, extracellular ma-
trix; GST, glutathione S–transferase; LAP, latency associated peptide;
LPS, lipopolysaccharide; LTBP-1, latent TGF-
 
b
 
 binding protein-1; MDC,
monodansylcadaverine; MLEC, mink lung epithelial cells; PAI-1, plasmi-
nogen activator inhibitor-1; TGF-
 
b
 
, transforming growth factor-
 
b
 
; WT,
wild type.
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muscle cells or pericytes, and lipopolysaccharide (LPS)–
stimulated, thioglycollate-elicited peritoneal macrophages
(30, 31, 44, 54). Components of this activation mechanism
include the serine protease plasmin, the cross-linking en-
zyme transglutaminase, LTBP-1, and the mannose 6-phos-
phate/insulin-like growth factor type II receptor, which ap-
pears to bind to mannose 6-phosphate residues in LAP
(16, 19, 31, 54, 55).
Interactions of the proteins involved in the activation of
large latent complex are not well understood. Plasmin can
release TGF-
 
b
 
 from large latent complex under cell-free
conditions (36). The mannose 6-phosphate/insulin-like
growth factor type II receptor binds forms of latent TGF-
 
b
 
,
but the role of this interaction is not clear (32). The role of
LTBP-1 or tissue transglutaminase in large latent complex
activation is not known. As part of an effort to character-
ize the activation process of large latent complex, we have
initiated studies to examine the potential interactions of
LTBP-1 and tissue transglutaminase.
LTBP consists of a family of glycoproteins of 
 
z
 
120–210
kD that contain a central core of EGF-like repeats and
multiple unique eight-cysteine repeats (22, 28, 43, 46, 64).
LTBPs are structurally similar to the microfibrillar pro-
teins fibrillin-1 and -2 (48, 50, 65). Defects in fibrillins are
responsible for the matrix fragility observed in patients
with Marfan syndrome and congenital contractural arach-
nodactyly (29, 47). The best characterized member of the
family is LTBP-1, which can exist as either short (LTBP-
1S) or long (LTBP-1L) forms (46). A number of cell types
secrete LTBP-1 as a higher order complex in which the
third eight-cysteine repeat in LTBP-1 is disulfide-linked to
the cysteine at position 33 of LAP (22a, 49). It is unknown
whether the short and long forms of LTBP-1 are expressed
differentially. LTBP facilitates the secretion of small latent
complex, participates in the activation of large latent com-
plex, targets large latent complex to the ECM of fetal rat
calvarial cells, fibroblasts, epithelial cells, and endothelial
cells, and contributes to the formation of fibrillar struc-
tures (13, 19, 41, 44, 59–61). LTBP-1S and -1L associate
differentially with the matrix, with LTBP-1L having a
greater affinity (46). Matrix association of LTBP-1 appears
to be covalent, as LTBP in the matrix is deoxycholate in-
soluble but is released upon proteolysis (Taipale, J., J. Sa-
harinen, K. Hedman, and J. Keski-Oja. 1994. 
 
Mol. Biol.
Cell.
 
 5[Suppl.]:311a). However, the mechanism of covalent
association between LTBP-1 and the ECM is unknown.
Transglutaminases are a family of structurally and func-
tionally related calcium-dependent enzymes that catalyze
the formation of isopeptide bonds between 
 
g
 
-carboxamide
groups of glutamine residues and 
 
e
 
-amino groups of lysine
residues (24, 33). The family is comprised of five members:
plasma Factor XIII, keratinocyte transglutaminase, tissue/
endothelial transglutaminase, epidermal transglutaminase,
and prostate transglutaminase. Although transglutaminase
does not have a signal sequence, the enzyme can be local-
ized to cell surfaces as well as the ECM and reacts to stabi-
lize interactions between extracellular substrates such as
plasminogen, fibronectin, nidogen, and vitronectin (3, 6,
37, 51, 63). Pericellular transglutaminase may play a role in
stabilizing cell and ECM interactions (24, 37). Transglu-
taminase is required for the conversion of large latent com-
plex to TGF-
 
b
 
 in several systems, including retinoid-treated
BAE cells, LPS-stimulated thioglycollate-elicited peritoneal
macrophages, and cocultures of BAE and bovine smooth
muscle cells (BSM) (30, 31, 44).
Because LTBP-1 is structurally homologous to micro-
fibrillar proteins that are stabilized by transglutaminase-
dependent cross-linking (10) and LTBP-2 has been local-
ized to elastin-associated microfibrils (22), we explored the
possibility that the covalent association between LTBP-1
and ECM proteins is catalyzed by transglutaminase. Here
we show that LTBP-1 and large latent complex are sub-
strates for transglutaminase both as isolated molecules
and in cell cultures. We demonstrate that matrix incorpo-
ration of LTBP-1 is transglutaminase-dependent and re-
quires the amino-terminal region of LTBP-1 and that ma-
trix association is an intermediate step in the activation
mechanism used by cells to generate TGF-
 
b
 
.
 
Materials and Methods
 
Materials
 
Human plasmin (10 U/ml), isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside (IPTG),
1-
 
o
 
-
 
n
 
-octyl-
 
b
 
-
 
d
 
-glucopyranoside (
 
n
 
-octylglucoside), Pefabloc SC, and pro-
tein A–agarose were purchased from Boehringer Mannheim Corp. (India-
napolis, IN). Cystamine, glutathione-agarose, guinea pig liver transgluta-
minase, monodansylcadaverine (MDC), and nonimmune rabbit serum were
purchased from Sigma Chemical Co. (St. Louis, MO). Pyrogen-poor BSA
was purchased from Pierce (Rockford, IL). 
 
l
 
-[
 
35
 
S]cysteine, 
 
35
 
S-labeled ex-
press translabel mix, and 
 
125
 
I-Na (pH 12–14, high concentration) were ob-
tained from Du Pont Company Biotechnology Systems (Wilmington,
DE). Recombinant human TGF-
 
b
 
1 was a gift from Berlex Biosciences
(South San Francisco, CA). Pan-neutralizing monoclonal mouse anti–TGF-
 
b
 
IgG1 was either purchased from Genzyme (Cambridge, MA) or donated by
Celtrix (Santa Clara, CA) (15). Recombinant human LTBP-1S, human
large latent complex, and small latent complex were provided by Drs.
Hideya Ohashi and Haruhiko Tsumura (KIRIN Brewery Co., Ltd., Phar-
maceutical Division, Gunma, Japan). Recombinant Factor XIII (166 kD)
was provided by Dr. P.D. Bishop (ZymoGenetics Inc., Seattle, WA) (7).
The human fibroblast LTBP-1S cDNA (pSV7d-BP13) was a gift from
Drs. K. Miyazono and C. Heldin (Ludwig Institute for Cancer Research,
Uppsala, Sweden) (28, 46). Ab 39, a polyclonal rabbit anti-LTBP IgG, was
a gift from Dr. K. Miyazono (40). Ab 39 was generated against human
LTBP purified from human platelets and recognizes LTBP-1 but not
LTBP-2 (28, 43).
 
Cell Culture
 
Human fibrosarcoma cells (HT 1080; American Type Culture Collection,
Rockville, MD) were grown in DME containing 10% (heat-inactivated)
FCS, 100 U/ml penicillin G, 100 
 
m
 
g/ml streptomycin sulfate, and 2 mM 
 
l
 
-glu-
tamine (P/S/Q). Rat osteosarcoma cells (UMR-106; American Type Cul-
ture Collection) were cultured in DME containing 10% (heat-inactivated)
FCS and P/S/Q. Chinese hamster ovary cells (CHO K1) were cultured in
 
a
 
-MEM containing 10% (heat-inactivated) FCS and P/S/Q.
Primary BAE and BSM cells were isolated and cultured in 
 
a
 
-MEM and
DME containing 10% (non–heat inactivated) calf serum plus P/S/Q, re-
spectively (53). Stimulated peritoneal macrophages were harvested from
Swiss Webster mice, which had been injected i.p. with 4% thioglycollate
broth and activated by LPS in vitro as previously described (44).
 
Expression and Purification of Glutathione
S–Transferase–LTBP-1S Fusion Proteins
 
Three fusion proteins, each consisting of glutathione S–transferase (GST)
fused to a region of human fibroblast LTBP-1S, were generated by ex-
pressing pGEX1n constructs encoding LTBP-1S fragments in HB101 
 
Es-
cherichia coli
 
 followed by purification using glutathione-agarose (57). Fu-
sion proteins GST-450, GST-1065, and GST-849 contain sequences from
the amino, middle, and carboxyl regions of human fibroblast LTBP-1S, re-
spectively (Fig. 1) (28, 46). 
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pGEX-450 was constructed by cloning a 450-bp BanI fragment of the
LTBP-1S cDNA BP13 (nucleotides 419–869) (28) into a SmaI site of
pGEX1n. The pGEX-1065 construct was prepared by ligating a 1065-bp
BamHI-EcoRI fragment of the LTBP-1S cDNA BP13 (nucleotides 1087–
2152) and BamHI-EcoRI–digested pGEX1n. The pGEX-849 construct
was generated by cloning an 849-bp StuI-SSpI fragment of the LTBP-1S
cDNA BP13 (nucleotides 3779–4628) in the SmaI site of pGEX1n.
Once the insert orientation and sequence were verified for each con-
struct, HB101 
 
E. coli
 
 were transformed with the pGEX1n plasmid (con-
trol) or a pGEX–LTBP-1S expression construct by electroporation (Cell
Porator; GIBCO BRL, Gaithersburg, MD). Fusion proteins were purified
from IPTG-induced bacteria using glutathione-agarose according to the
manufacturer’s instructions (Pharmacia LKB Biotechnology, Inc., Piscat-
away, NJ). The integrity and apparent mol wts of the fusion proteins were
verified by reducing SDS-PAGE followed by Coomassie brilliant blue R
staining (26).
 
Preparation and Characterization of Antibodies to 
GST–LTBP-1S Fusion Proteins
 
Polyclonal rabbit antisera raised against purified GST-450, GST-1065, or
GST-849 fusion proteins were prepared by Cocalico Biologicals, Inc.
(Reamstown, PA). Affinity-purified anti-450, anti-1065, and anti-849 IgG
were prepared by incubation of antisera with tosyl-activated agarose
(Pierce), to which fusion proteins had been coupled as recommended by
the manufacturer. Antibodies were characterized by Western blotting and
immunoprecipitation of recombinant large latent complex, recombinant
LTBP-1, or HT 1080 conditioned medium (CM).
Western blotting was performed using nonreducing or reducing condi-
tions. Proteins separated by SDS-PAGE were transferred to Immobilon-P
membrane (Millipore Corp., Bedford, MA) (62). Membranes were blocked
with PBS containing 5% Carnation nonfat milk (Nestle Food Co., Glen-
dale, CA), incubated with either Ab 39 serum or serum raised against
GST–LTBP fusion proteins in blocking buffer, washed with Tris-buffered
saline (150 mM NaCl, 50 mM Tris-HCl, pH 7.4) and 1% Triton X-100, in-
cubated with either goat anti–rabbit IgG conjugated to alkaline phos-
phatase (Promega Corp., Madison, WI) or donkey anti–rabbit IgG conju-
gated to horseradish peroxidase (Amersham Corp., Arlington Heights,
IL), and washed as described above. Alkaline phosphate– and horseradish
peroxidase–containing immune complexes were revealed by incubating
the membrane with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tet-
razolium phosphatase substrate (Kirkegaard and Perry Laboratories, Inc.,
Gaithersburg, MD) and enhanced chemiluminescence detection reagents
(ECL; Amersham Corp.), respectively. The immunoreactivity of antisera
to GST–LTBP-1S fusion proteins was compared to that of Ab 39, a poly-
clonal antiserum raised against intact LTBP-1 purified from human plate-
lets (40). The mol wts of large latent complex and LTBP-1 observed in our
experiments are consistent with those reported by others (data not shown)
(28, 40).
Immunoprecipitations were performed using large latent complex (2–5
 
m
 
g) or LTBP-1 (2–5 
 
m
 
g) iodinated using 250 
 
m
 
Ci 
 
125
 
I-Na and 20 
 
m
 
g/ml
chloramine T as described by McConahey et al. (39). 
 
35
 
S-labeled HT 1080
CM was prepared by incubating confluent cultures overnight with DME
deficient in cysteine and methionine (Gibco Laboratories, Grand Island,
NY), 100 
 
m
 
Ci/ml 
 
35
 
S-express translabel mix, and 1% normal DME culture
medium. Iodinated proteins and metabolically labeled CM were immuno-
precipitated with Ab 39 serum or antiserum generated against one of the
three fusion proteins. Radiolabeled proteins were incubated with antise-
rum for 1–1.5 h at room temperature. Immune complexes were precipi-
tated using protein A–agarose, washed with Tris-buffered saline and 1%
Triton X-100, and transferred to a 1.5-ml test tube followed by a water
wash. Protein A–precipitated complexes were solubilized in nonreducing
or reducing Laemmli sample buffer and separated by SDS-PAGE. Iodi-
nated proteins were visualized by autoradiography, and metabolically la-
beled proteins were visualized by fluorography of gels treated with 1 M
sodium salicylate, dried, and exposed to film (X-OMAT; Eastman Kodak
Co., Rochester, NY) at 
 
2
 
80
 
8
 
C for 7–10 d. Anti-450 and anti-849 antisera
immunoprecipitated radiolabeled forms of LTBP-1 but were not as effec-
tive as Ab 39 (data not shown). Anti-1065 antisera failed to recognize any
of the radiolabeled preparations containing LTBP-1 (data not shown).
Anti-1065 antiserum was used as a negative control because its reactivity
with nondenatured LTBP-1 was negligible. These results indicated that
the antibodies to the amino- and carboxyl-terminal regions could be used
for immunoprecipitation of LTBP-1 and in experiments examining the
role of the amino and carboxyl termini of LTBP-1 in the cross-linking and
activation of large latent complex.
 
Cross-Linking Reactions by Transglutaminase
 
Guinea pig liver transglutaminase was used at an enzyme/substrate molar
ratio of 1:5. Substrates for cross-linking reactions were iodinated using 250
 
m
 
Ci 
 
125
 
I-Na and 20 
 
m
 
g/ml chloramine T (39). Rabbit nonimmune IgG (1
mg/ml) was added as a carrier protein to all enzymatic assays, as IgG is not a
substrate for tissue transglutaminase (8). Human fibronectin (Collabora-
tive Biomedical Products, Bedford, MA), recombinant large latent com-
plex, and recombinant LTBP-1, all used at 167 nM, were incubated at
37
 
8
 
C for 1 h in 1.5-ml siliconized test tubes containing transglutaminase,
10 mM Tris-HCl, pH 8.0, 0.5 mM DTT, and 15 mM CaCl
 
2
 
. Specificity of
cross-linking reactions was verified by including either 100 
 
m
 
M MDC, a
competitive transglutaminase inhibitor, or 30 mM EDTA (33). Reactions
were stopped by addition of reducing SDS-PAGE Laemmli sample buffer.
Cross-linked proteins were separated by reducing SDS-PAGE, and gels
were examined by PhosphorImager scanning analysis (Molecular Dynam-
ics, Sunnyvale, CA).
To identify regions of LTBP-1 that contain transglutaminase-reactive
sites, cross-linking reactions were performed as described above in the
presence of either affinity-purified antibodies generated against GST–
LTBP-1S fusion proteins or protein A–purified Ab 39, as well as 0.1 mg/
ml 
 
l
 
-cystine, which was needed to minimize disulfide exchange within and
between proteins.
 
Immunoprecipitation of Matrix Digests Prepared from 
Metabolically Labeled Cells
 
Subconfluent cultures were incubated in DME deficient in cysteine and
methionine for 1 h at 37
 
8
 
C. Cultures were treated with 0.06% DMSO
(control), 50 
 
m
 
M MDC, 100 
 
m
 
M cystamine, or affinity-purified antibodies
during the starvation and subsequent pulse-chase period. After the cells were
metabolically labeled for 3 h with 100 
 
m
 
Ci/ml of 
 
l
 
-[
 
35
 
S]cysteine in cysteine,
methionine-deficient DME supplemented with 2% Optimem (Gibco Lab-
oratories), and 150 
 
m
 
g/ml of 
 
l
 
-methionine, they were transferred to Opti-
mem medium for an overnight incubation at 37
 
8
 
C in a 5% CO
 
2
 
 atmo-
sphere. ECMs were prepared from metabolically labeled cells after lysis
with 0.5% sodium deoxycholate in Tris-buffered saline (10 mM Tris-HCl,
pH 8.0, and 150 mM NaCl) (59). Matrices were digested with 0.3 U/ml
plasmin in 0.1% 
 
n
 
-octylglucoside, 3 mM MgCl
 
2
 
, 3 mM CaCl
 
2
 
, 10 mM Tris-
HCl, pH 8.0, and 150 mM NaCl for 1 h at 37
 
8
 
C. Plasmin was inhibited by
8 mM Pefabloc SC and 1 
 
m
 
g/ml aprotinin. Digests normalized to total
TCA-precipitable cpm as described by Harlow and Lane (26) were incu-
bated with either nonimmune or Ab 39 serum, and immune complexes
were precipitated using protein A–agarose. Washed immunoprecipitates
were separated by reducing SDS-PAGE and visualized by fluorography.
 
Immunoprecipitation of Matrix Digests Prepared from 
UMR-106 Matrices
 
35
 
S-labeled CM were prepared using BAE or UMR-106 confluent cultures
that were metabolically labeled for 20 h with 100 
 
m
 
Ci/ml of 
 
l
 
-[
 
35
 
S]cysteine.
Metabolically labeled CM were concentrated fivefold using Centricon-30
ultrafilters (Amicon, Beverly, MA) and immediately added to UMR-106
ECMs prepared using 0.5% sodium deoxycholate in Tris-buffered saline
(59). Additions of antibodies or 50 
 
m
 
M MDC were done concurrently. To
Figure 1. Regions of LTBP-1S expressed in bacteria as GST–
LTBP-1S fusion proteins. Three GST–LTBP-1S fusion proteins
(GST-450, GST-1065, and GST-849) were generated by express-
ing regions of the human LTBP-1S cDNA using pGEX1n in E. coli.
Representation of LTBP-1S was adapted from Kanzaki et al. (28). 
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catalyze the cross-linking of large latent complex present in radiolabeled
CM and UMR-106 matrix proteins, thrombin-activated Factor XIII (Fac-
tor XIIIa) was added (7). Each matrix incorporation reaction was done
using 1 ml of concentrated radiolabeled CM, 3 nmol of DTT-pretreated
Factor XIIIa, and 4 mM CaCl
 
2
 
 in Tris-buffered saline on 78.5 cm
 
2
 
 of
UMR-106 ECM for 1 h at 37
 
8
 
C. The LTBP-1 content of UMR-106 matri-
ces was analyzed by immunoprecipitating plasmin digests of matrices with
Ab 39 followed by SDS-PAGE and fluorography of immunoprecipitates
as described in this manuscript.
 
Transient Transfection of CHO Cells with LTBP-1S 
cDNA Constructs
 
Three LTBP-1S cDNA constructs were generated using the pcDNA3 (In-
Vitrogen, San Diego, CA) expression vector for transient expression of CHO
cells. The three constructs are pcDNA3–wild type (WT), pcDNA-
 
D
 
N293,
and pcDNA-
 
D
 
N441 (see Fig. 8 
 
A
 
). To generate pcDNA3-WT LTBP-1S,
the fragment 68–4543 (DraI-DraI) of the human LTBP-1S cDNA BP13
(28) was subcloned into pcDNA3 downstream of the human cytomeg-
alovirus immediate early gene promoter. pcDNA3-
 
D
 
N293 and pcDNA3-
 
D
 
N441 were obtained by digesting BP13 with HpaI and DraI (nucleotides
1414–4543), and ScaI and DraI (nucleotides 970–4543), respectively; these
fragments were fused in frame with the baculovirus glycoprotein GP67
signal sequence as described elsewhere (22a) and subcloned into pcDNA3.
CHO cells were transiently transfected using lipofectamine (Gibco
Laboratories) according to the manufacturer’s instructions. Briefly, cells
plated in 35-mm dishes received 1–4 
 
m
 
g of plasmid DNA premixed with li-
pofectamine in Optimem. After 24 h, media were harvested and replaced
with fresh Optimem. Transfected cultures were incubated for an addi-
tional 24 h, at which time media were collected and matrix digests were
prepared.
 
Western Blotting CM and Matrix Digests of Transfected 
CHO Cultures
 
CM and matrix digests were prepared from transfected CHO cultures for
Western blotting analysis using Ab 39. The CM collected after the first
and second 24 h of transfection were pooled and concentrated 10-fold.
The concentrated CM and matrix digests were mixed with nonreducing
sample buffer for SDS-PAGE. Separated proteins were transferred elec-
trophoretically to Immobilon-P for immunoblotting with Ab 39 serum, and
immune complexes were visualized using chemiluminescence reagents as
described earlier.
 
Preparation of CM from Cultures of BAE and BSM 
Cells and Stimulated Macrophages
 
Serum-free CM were prepared from homo- and heterotypic cultures of
BAE and BSM cells and from LPS-stimulated thioglycollate-elicited mac-
rophages as described in previous reports (44, 53, 54). CM collected after
14 h were immediately bioassayed for TGF-
 
b
 
 activity (see below). TGF-
 
b
 
–dependent activity was verified by adding neutralizing anti–TGF-
 
b
 
 IgG
to parallel test samples before assay. Total TGF-
 
b
 
, which consists of cell-
activated plus latent TGF-
 
b
 
, was quantitated after heating CM at 85
 
8
 
C for
12 min, a procedure known to convert latent TGF-
 
b to TGF-b, before as-
say (9).
Mink Lung Epithelial Cells–Luciferase Assay
for TGF-b Activity
This quantitative bioassay for TGF-b is based on the ability of TGF-b to
stimulate plasminogen activator inhibitor-1 (PAI-1) expression (1). Mink
lung epithelial cells (MLEC), stably transfected with an expression con-
struct containing a truncated PAI-1 promoter fused to the firefly luci-
ferase reporter gene, were incubated overnight with CM harvested from
either stimulated macrophages or cultures of BAE and BSM cells. Recom-
binant TGF-b1 in a-MEM or DME with 0.1% BSA was used to generate
a standard curve of TGF-b activity. Luciferase activity was quantitated us-
ing a luciferin substrate buffer in a ML3000 Microtiter Plate Luminometer
(Dynatech Laboratories Inc., Chantilly, VA) (1).
Wound Migration Assay for TGF-b Activity
To measure TGF-b present in CM, wound migration assays were per-
formed as described by Sato and Rifkin (52). This bioassay is based on the
ability of TGF-b to inhibit endothelial cell migration. Confluent monolay-
ers of BAE cells plated in a 35-mm dish were wounded with a razor blade
and incubated with serum-free test samples for 18–20 h at 378C in a 5%
CO2 atmosphere. Cells were fixed and stained with 0.5% crystal violet in
20% methanol (44). BAE cells that had migrated from the edge of the
wound were counted in successive 125-mm increments at 1003 using a
light microscope with an ocular grid. The number of cells migrating be-
yond 125 mm from seven different fields was averaged. Data are presented
as a percentage of control, where the control sample consists of homotypic
BAE and BSM media mixed 4:1.
Results
Transglutaminase Reactivity of LTBP and Large
Latent Complex
The apparent covalent interaction of LTBP-1 and ECM
(33, 36) as well as the requirement for tissue transglutami-
nase for activation of large latent complex described for
various culture systems suggested (30, 31, 44) that LTBP-1
and large latent complex might be substrates for trans-
glutaminase. Therefore, iodinated recombinant LTBP-1
or large latent complex was incubated with guinea pig liver
transglutaminase and analyzed by reducing SDS-PAGE.
Samples incubated with transglutaminase revealed high mol
wt complexes visible at the top of the 3% stacking poly-
acrylamide gel as well as intermediate-sized complexes at
the interface between the 3% stacking and 7% resolving
gels, indicating that both LTBP-1 and the large latent com-
plex were polymerized by transglutaminase (Fig. 2). The
efficiency of cross-linking of either LTBP-1 or large latent
complex by transglutaminase varied among experiments
as the relative amounts of polymerized and unreacted pro-
tein differed somewhat between reactions (data not shown).
Figure 2. SDS-PAGE analysis of cross-linking large latent com-
plex or LTBP-1 by transglutaminase. (A) Iodinated large latent
complex (LLC) was incubated with guinea pig liver transglutami-
nase (TGase) in the presence or absence of EDTA and CaCl2.
Proteins were separated by reducing SDS-PAGE using a 3%
stacking and 7% resolving gel and were revealed by PhosphorIm-
ager scanning. (B) Iodinated LTBP-1 was incubated with guinea
pig liver transglutaminase in the presence or absence of MDC.
Proteins were separated by reducing SDS-PAGE using a 3%
stacking and 12% resolving gel and were revealed by Phosphor-
Imager scanning.Nunes et al. Latent Transforming Growth Factor-b Activation 1155
This may reflect differences in the specific activity of dif-
ferent transglutaminase preparations. The observed poly-
merization of LTBP-1 and large latent complex implies
that LTBP-1 and the large latent complex each contain
both acyl donor and acyl acceptor sites necessary for for-
mation of isopeptide bonds. Cross-linking LTBP-1 or large
latent complex was Ca21 dependent and transglutaminase
specific as generation of high mol wt complexes was atten-
uated by the addition of EDTA or MDC (Fig. 2) (33). MDC
acts as a competitive inhibitor of transglutaminase by com-
peting for reactive glutamines (33). As large latent complex
consists of small latent complex and LTBP-1, transglutam-
inase-dependent cross-linking of large latent complex to
itself could involve either LTBP-1, small latent complex,
or both. Cross-linking reactions using tissue transglutami-
nase and recombinant small latent complex also yielded
high mol wt complexes (data not shown), indicating it also
contains acyl donor and acceptor sites. However, this reac-
tion is not responsible for the matrix incorporation of
large latent complex as shown by antibody inhibition stud-
ies (see below). Iodination of either LTBP-1 or large la-
tent complex did not generate reactive sites absent in non-
radiolabeled proteins because transglutaminase-catalyzed
incorporation of MDC into nonradiolabeled LTBP-1 or
large latent complex was observed using black light to vi-
sualize MDC-containing proteins resolved by SDS-PAGE
(data not shown) (6).
Transglutaminase-dependent Cross-Linking of LTBP-1 
and ECM by Cells
Both free LTBP-1 and large latent complex have been de-
scribed to associate covalently with ECMs generated by fi-
broblasts, endothelial cells, and epithelial cells (59–61). The
results described above suggested the hypothesis that ma-
trix incorporation of LTBP-1 and large latent complex oc-
curs through transglutaminase-catalyzed cross-linking of
LTBP-1 and matrix proteins. To test this hypothesis, we
first confirmed that homotypic cultures of HT 1080 and
BAE cells as well as heterotypic cultures of BAE and BSM
cells generate matrix-associated LTBP-1. ECM-bound
LTBP-1 was analyzed by experiments in which matrix di-
gests prepared from metabolically labeled cultures were
immunoprecipitated using Ab 39. Immunoprecipitated ma-
trix digests prepared from HT 1080 and BAE cells, as well
as from cocultures of BAE and BSM cells, revealed frag-
ments of 120–140 and 180–210 kD, respectively (Fig. 3).
These matrix fragments specifically reacted with Ab 39 be-
cause they were not observed in control immunoprecipita-
tion experiments with nonimmune serum (data not shown).
The difference in mol wt of matrix fragments immunopre-
cipitated with Ab 39 obtained from HT 1080 and vascular
cells is consistent with a report that LTBP-1 recovered
from matrix digests prepared from different cell types var-
ies in mol wt (61). The differences in size of the LTBP-1
fragments recovered from the ECM may reflect variations
in matrix composition, in differential expression of LTBP-1
isoforms incorporated into the ECM (26), or in endoge-
nous proteolytic activities in the cell culture.
Having confirmed that LTBP-1 was present in the ECM,
we next examined whether the incorporation of endoge-
nous LTBP-1 into the ECM by cells was transglutaminase
dependent. Matrices were prepared from cultures meta-
bolically labeled in the presence of the transglutaminase
competitive inhibitors MDC or cystamine (33), and the
LTBP-1 content of the ECM was examined by digesting
matrices with plasmin and immunoprecipitating the di-
gests with Ab 39 followed by SDS-PAGE analysis. Signifi-
cantly less LTBP-1 was recovered from matrices prepared
from cultures of HT 1080, BAE, and BSM cells treated
with MDC or cystamine than from control cultures (Fig. 4,
A and B). Matrix digests from cultures incubated with
transglutaminase inhibitors contained 2–10-fold less LTBP-1
than respective control cultures as determined by laser
scanning densitometry. Cells treated with MDC incorpo-
rated less LTBP-1 into the matrix than did cystamine-
treated cells (Fig. 4 A, second and fourth lanes), probably
because the concentration of cystamine used in cultures
was below the saturating concentration needed to com-
Figure 3. Presence of LTBP-1
in matrix digests prepared
from HT 1080, BAE, and co-
cultures of BAE and BSM
cells. Subconfluent cultures
of HT 1080 and BAE cells
and cocultures of BAE and
BSM cells were pulsed with
[35S]cysteine for 3 h and
chased overnight. Matrices
were prepared, followed by
digestion with 0.3 U/ml of
plasmin. Digests were immu-
noprecipitated using Ab 39
serum followed by protein
A–agarose. Immunoprecipi-
tates were analyzed by SDS-
PAGE followed by fluorogra-
phy. Þ, 120–140-kD LTBP-1
matrix fragments. ®, 180–
210-kD LTBP-1 matrix frag-
ments.
Figure 4. LTBP-1 content of matrix digests prepared from cul-
tures treated with transglutaminase inhibitors. (A) Subconfluent
cultures of HT 1080 cells were either untreated or treated with
50 mM MDC, 0.06% DMSO, or 100 mM cystamine during the 3-h
pulse with [35S]cysteine and overnight chase. (B) Subconfluent
homotypic and heterotypic cultures of BAE and BSM cells were
either untreated or MDC-treated (50 mM) during the pulse-chase
period as described for HT 1080 cells. Matrix digests were pre-
pared from all cultures and immunoprecipitated using Ab 39 se-
rum. Immunoprecipitates were analyzed by SDS-PAGE followed
by fluorography.The Journal of Cell Biology, Volume 136, 1997 1156
pletely inhibit pericellular transglutaminase activity. Lev-
els of MDC or cystamine greater than those used in our
experiments may have been necessary to completely in-
hibit matrix incorporation of LTBP-1. However, higher
levels of these transglutaminase inhibitors were toxic to
cells. To insure that results obtained using transglutami-
nase inhibitors did not result from effects on total protein
synthesis and secretion, all matrix digests were normalized
to total TCA precipitable cpms before immunoprecipitat-
ing with Ab 39 serum (11). In addition, the effect of MDC
on protein synthesis and secretion was monitored by im-
munoprecipitating fibronectin from metabolically labeled
CM harvested from untreated and MDC-treated HT 1080
cells. Fibronectin levels in treated and untreated HT 1080
CM were found to be equivalent (data not shown). As-
suming that the transglutaminase inhibitors did not selec-
tively affect LTBP-1 expression, the decreased amount of
LTBP-1 observed in matrix digests prepared from cultures
treated with inhibitors suggests that the matrix incorpora-
tion of LTBP-1 is transglutaminase dependent.
In similar experiments, twice as much LTBP-1 was re-
covered from BAE matrix digests than from BSM matrix
digests as determined by immunoprecipitating plasmin di-
gests of metabolically labeled ECM using Ab 39 (Fig. 4 B).
This may reflect higher levels of tissue transglutaminase
expression by BAE cells compared to BSM cells rather
than differences in LTBP-1 expression, as BSM cells have
been reported to produce more LTBP-1 than BAE cells
(19, 31).
To establish whether the effect of transglutaminase in-
hibitors on the matrix incorporation of LTBP-1 as ob-
served in culture was a consequence of altered matrix as-
sembly and stabilization, matrix incorporation reactions
were done using matrices from untreated UMR-106 cells,
35S-labeled BAE CM as an exogenous source of large la-
tent complex, and the plasma transglutaminase Factor XIIIa.
Matrices from UMR-106 cells were used because UMR-
106 cells produce latent TGF-b only as the small latent
complex (12). We confirm that large latent complex was
not generated by our UMR-106 cells, as no LTBP-1 was
detected in Ab 39 immunoprecipitates of 35S-metabolically
labeled CM (Fig. 5 A, first lane). Metabolically labeled CM
from BAE cells was used as an exogenous source of large
latent complex, as we have previously observed (19), and
confirmed that they produce LTBP-1 as large latent com-
plex (220 kD; Fig. 5 A, second lane ). The LTBP-1 content
of UMR-106 matrices incubated with radiolabeled BAE
CM in the absence or presence of MDC was analyzed by
digesting matrices with plasmin and immunoprecipitating
digests with Ab 39 (Fig. 5 B). Visualization of immunopre-
cipitates by fluorography revealed that matrices reacted
with transglutaminase and BAE CM contained cross-
linked LTBP-1 (Fig. 5 B, first lane), whereas digests from a
parallel matrix reaction containing MDC did not (Fig. 5 B,
third lane). Control matrix incorporation reactions of
UMR-106 CM and UMR-106 matrices confirmed that the
ECM of UMR-106 cells does not contain endogenous
LTBP-1, as no LTBP-1 was recovered from matrix digests.
Results from matrix incorporation experiments indicate
that the decreased levels of matrix-associated LTBP-1 ob-
served in cultures treated with MDC were due to the inhi-
bition of cross-linking by transglutaminase rather than ef-
fects on matrix assembly and stability.
Identification of LTBP-1 Domains Involved in
Cross-Linking by Transglutaminase
Results presented in Figs. 2, 4, and 5 demonstrate that
LTBP-1 and large latent complex are substrates for trans-
glutaminase and that matrix incorporation of large latent
complex is transglutaminase dependent. To determine
whether LTBP-1 is necessary for cross-linking of large la-
tent complex, antibodies to intact LTBP-1 or different
LTBP-1 sequences were included in cross-linking reac-
tions of transglutaminase and iodinated large latent com-
plex as described previously. Ab 39 inhibited transglutam-
inase-dependent cross-linking of large latent complex, as
measured by the absence of polymerized large latent com-
plex present as a high mol wt band in the 3% stacking
polyacrylamide SDS gel (Fig. 6 A). Ab 39 did not interfere
with cross-linking of small latent complex by transglutami-
nase (data not shown). This indicated that cross-linking of
the large latent complex probably requires lysine or gluta-
mine residues present in LTBP-1. To identify what region
of LTBP-1 contains transglutaminase reactive residues, af-
finity-purified anti-450 and anti-849 IgG were added to
transglutaminase-dependent cross-linking reactions of io-
dinated LTBP-1 and large latent complex. Addition of
anti-450 IgG blocked cross-linking of large latent complex
and LTBP-1 to itself, as measured by the decreased forma-
tion of high mol wt polymers observed in the stacking gel,
whereas nonimmune, anti-849, and anti-1065 IgGs did not
(Fig. 6). These findings indicate that transglutaminase-
reactive sites are present in the amino-terminal region of
LTBP-1.
Figure 5. Cross-linking LTBP-1 in BAE CM to UMR-106 ECM
by Factor XIIIa. (A) UMR-106 and BAE cultures were metabol-
ically labeled using [35S]cysteine and CM were immunoprecipi-
tated using Ab 39 serum. LTBP-1 immunoprecipitates (IPs) from
CM were separated by nonreducing SDS-PAGE and visualized
by fluorography. (B) Matrix incorporation reactions were done
using metabolically labeled CM from BAE or UMR-106 cells and
UMR-106 ECMs. The cross-linking reaction was catalyzed by
Factor XIIIa in the absence (2) or presence (1) of 50 mM MDC.
Matrix digests were prepared by plasmin digestion and immuno-
precipitated using Ab 39 serum. Immunoprecipitates were ana-
lyzed by reducing SDS-PAGE and fluorography.Nunes et al. Latent Transforming Growth Factor-b Activation 1157
To establish whether the amino-terminal region also
contained transglutaminase reactive sites involved in the
matrix association of LTBP-1, affinity-purified antibodies
to the three GST–LTBP-1S fusion proteins were added to
cultures of HT 1080 and BAE cells throughout a pulse-
chase metabolic labeling period. Because HT 1080 cells
are proteolytically more active than BAE cells (18), we
added aprotinin, a serine protease inhibitor, to HT 1080
cultures to prevent antibodies from being degraded by en-
dogenous proteases. The amount of LTBP-1 incorporated
in the matrix by antibody-treated HT 1080 and BAE cells
was assessed by immunoprecipitating matrix digests with
Ab 39 followed by SDS-PAGE. The immunoprecipitation
experiments revealed that the amount of LTBP-1 recov-
ered from matrices prepared from cultures treated with
anti-450 IgG was significantly decreased compared to that
recovered from cultures treated with nonimmune, anti-
1065, or anti-849 IgG (Fig. 7 A). Laser scanning densitom-
etry of fluorographs revealed that digests prepared from
HT 1080 and BAE cultures receiving anti-450 IgG con-
tained 5–10-fold and 70-fold less LTBP-1, respectively, than
matrices prepared from cultures treated with the other an-
tibodies. Addition of aprotinin did not affect the deposi-
tion of LTBP-1 into the matrix, as the cpms recovered by
immunoprecipitating matrix digests prepared from aproti-
nin-treated and untreated cultures with Ab 39 were similar
(data not shown). The weaker effect of anti-450 IgG on
HT 1080 versus BAE cells may reflect degradation of the
antibodies by metalloproteases; however, this was not ver-
ified. These results support findings reported by others
that incorporation of LTBP-1 into the matrix requires its
amino-terminal residues (46, 49).
To confirm the observation that addition of anti-450
IgG to cells producing large latent complex interferes with
the covalent incorporation of the complex to the ECM,
matrix incorporation reactions were done using UMR-106
matrices, 35S-labeled BAE CM, and Factor XIIIa, as de-
scribed earlier, in the presence of antibodies to GST–
LTBP-1S fusion proteins. Western blotting analysis of ma-
trix digests with Ab 39 indicated that addition of anti-450
IgG attenuated matrix deposition of large latent complex,
as less LTBP-1 was present in digests from matrix incorpo-
ration reactions containing anti-450 IgG compared to those
receiving nonimmune, anti-1065, or anti-849 IgG (Fig. 7 B).
Results from these matrix incorporation reactions confirm
Figure 6. Effect of antibodies to LTBP-1 on
transglutaminase cross-linking of large latent
complex or LTBP-1. Ab 39 IgG (0.2 mg/ml) and
affinity-purified IgGs (0.8 mg/ml) generated
against GST-450, GST-1065, or GST-849 were
added to transglutaminase cross-linking reac-
tions of iodinated large latent complex (LLC)
(A) or LTBP-1 (B). The presence of high mol wt
complexes was revealed by reducing SDS-PAGE
using a 3% stacking and 7% resolving gel fol-
lowed by PhosphorImager scanning.
Figure 7. Effect of antibodies to LTBP-1 on matrix incorporation
of LTBP-1. (A) Subconfluent cultures of HT 1080 and BAE cells
were treated during the 3-h pulse and overnight chase labeling
period with either protein A–purified nonimmune IgG or affin-
ity-purified IgGs (20 mg/ml) generated against GST-450, GST-
1065, or GST-849. HT 1080 cultures also received 50 mg/ml apro-
tinin to prevent degradation of exogenously added antibodies.
Matrix digests were prepared and immunoprecipitated using Ab
39 followed by SDS-PAGE and fluorography. (B) Matrix incor-
poration reactions of 35S-labeled BAE CM and UMR-106 ECMs
were done in the absence (2) of additions or in the presence of
protein A–purified non-immune rabbit IgG or affinity-purified
IgGs (20 mg/ml) generated against GST-450, GST-1065, and
GST-849. Matrix digests were prepared as previously described
and their LTBP-1 content was analyzed by immunoblotting using
Ab 39 serum as described in Materials and Methods.The Journal of Cell Biology, Volume 136, 1997 1158
that cross-linking large latent complex to the ECM in-
volves transglutaminase reactive residues at the amino ter-
minus of LTBP-1.
Transglutaminase Reactivity of
Amino-truncated LTBP-1S
The antibody to the amino terminus of LTBP-1S (anti-450
IgG) identified the amino-terminal region of LTBP-1 as
containing transglutaminase-reactive sites. However, lo-
calization of reactive residues within the amino terminus is
not possible using antibodies, as their inhibitory effect may
be due to steric hindrance rather than binding to reactive
residues. To identify domains within the amino-terminal
region of LTBP-1S that contain the transglutaminase-reac-
tive site(s), amino-terminal truncated mutants DN293 and
DN441 LTBP-1S cDNAs (Fig. 8 A) were constructed for
transient transfection of CHO cells. Control cultures were
either untransfected or WT LTBP-1S cDNA–transfected
cells. CHO cells transfected with WT, DN293, or DN441
LTBP-1S cDNA expressed and secreted LTBP-1S protein
accordingly as determined by Western blotting CM using
Ab 39 (Fig. 8 B). Untransfected (Fig. 8 B) cells, as well as
mock (pcDNA3-cat) transfected cells (data not shown),
produce low levels of LTBP-1 compared to cells trans-
fected with LTBP-1S cDNA constructs. To determine if
CHO cells incorporate LTBP-1S into ECM, matrix digests
were prepared by plasmin treating deoxycholate-extracted
matrices followed by immunoblotting using Ab 39. Matrix
digests prepared from cells transfected with WT and
DN293 LTBP-1S cDNA contained LTBP-1S, whereas lit-
tle to no LTBP-1S was detected in digests from untrans-
fected and DN441 LTBP-1S cDNA–transfected cells (Fig.
8 B). To determine whether matrix association of WT and
DN293 LTBP-1S was transglutaminase dependent, MDC
was added to untransfected and transfected CHO cultures.
Western blotting analysis of the LTBP-1S content of ma-
trix digests generated from MDC-treated transfected CHO
cells revealed negligible levels of LTBP-1S present in di-
gests from WT and DN293 LTBP-1S cDNA–transfected
cells, indicating that matrix association was transglutami-
nase dependent (data not shown). Results from the LTBP-
1S transfection experiments indicate that, unlike DN441
LTBP-1S,  DN293 LTBP-1S was cross-linked to matrix sug-
gesting that residues 294–441 are critical to the trans-
glutaminase-dependent reactivity of LTBP-1S.
Effect of Antibodies to GST–LTBP-1S Fusion Proteins 
on Latent TGF-b Activation
Activation of latent TGF-b by cocultures of BAE and
BSM cells as well as by stimulated macrophages requires
transglutaminase and LTBP-1 (19, 31, 44). Transglutami-
nase-dependent cross-linking of LTBP-1 into the matrix
by cocultures is inhibited by anti–LTBP-1 antibodies (Fig.
4 B). Therefore, we examined whether antibodies to GST–
LTBP-1S fusion proteins affected activation of latent TGF-b
using cocultures of BAE and BSM cells and cultures of
stimulated macrophages.
Serum-free heterotypic cultures of BAE and BSM cells
were used as a cell system that generates mature TGF-b
from endogenous large latent complex (14). Control cul-
tures were serum-free homotypic cultures of BAE and
BSM cells. The cocultures of BAE and BSM cells received
either affinity-purified antibodies to one of the three
GST–LTBP-1S fusion proteins, protein A–purified Ab 39,
or nonimmune IgG, as indicated in Fig. 9. After an over-
night incubation, CM from these cultures were bioassayed
immediately for mature TGF-b using the MLEC-luciferase
assay. These experiments revealed that CM from cocul-
tures treated with Ab 39, anti-450, or anti-849 IgG con-
tained less mature TGF-b than CM from untreated cocul-
tures or cocultures treated with nonimmune or anti-1065
IgG (Fig. 9 A). We previously observed that Ab 39 IgG
blocks latent TGF-b activation by cocultures of BAE and
BSM cells (19). To verify that the measured luciferase ac-
tivity was TGF-b dependent, neutralizing anti–TGF-b IgG
was added to CM from untreated cocultures and found to
inhibit 86% of the luciferase response (Fig. 9 A), indicat-
ing that most of the measured luciferase activity was TGF-b
dependent. Anti-450 and anti-849 IgG blocked TGF-b
generation at ID50’s of 20 and 1 mg/ml, respectively. CM
from cocultures treated with the anti–LTBP-1S IgGs con-
tained levels of latent TGF-b similar to those from un-
treated cocultures, as determined by the MLEC-luciferase
assay (data not shown). Furthermore, addition of the anti–
LTBP-1S IgGs to CM from untreated cocultures did not
inhibit TGF-b activity (data not shown). Therefore, the ef-
Figure 8. Expression and matrix incorporation of amino-trun-
cated LTBP-1S mutants by CHO cells. (A) LTBP-1S cDNA con-
structs were generated by subcloning LTBP-1S cDNAs into
pcDNA3 for transient transfection of CHO cells. pcDNA3-WT
LTBP-1S encodes the entire coding sequence of LTBP-1S.
pcDNA3-DN293 and -DN441 LTBP-1S encode LTBP-1S trun-
cated at the amino terminus by 293 and 441 amino acids, respec-
tively. (B) CM from untransfected (2) and LTBP-1S cDNA–
transfected CHO cells were immunoblotted using Ab 39 serum.
The LTBP-1S content of matrix digests from corresponding cul-
tures was analyzed by immunoblotting digests using Ab 39 serum.Nunes et al. Latent Transforming Growth Factor-b Activation 1159
fects of the antibodies did not result from changes in total
TGF-b levels.
The results obtained using the MLEC-luciferase assay
to measure mature TGF-b levels present in coculture CM
were confirmed using the wound migration assay, in which
the inhibitory effect of TGF-b on endothelial cell migra-
tion is quantitated. We observed that CM from cocultures
of BAE and BSM cells treated with Ab 39, anti-450, or
anti-849 IgG did not inhibit the migration of BAE cells,
nor did anti–TGF-b IgG–containing CM from untreated co-
cultures (Fig. 9 B). CM from cocultures treated with non-
immune or anti-1065 IgG inhibited the migration of endo-
thelial cells by z50% (Fig. 9 B). These results are similar
to those obtained using the MLEC-luciferase assay, indi-
cating that less TGF-b is present in CM prepared from
cocultures treated with Ab 39, anti-450, or anti-849 IgG.
To determine whether the inhibitory effect of anti-450
or anti-849 IgG on latent TGF-b activation was specific to
cocultures of BAE and BSM cells, we examined whether
these antibodies abrogated TGF-b formation by LPS-
stimulated thioglycollate-elicited peritoneal macrophages,
another cell system previously demonstrated to convert
large latent complex to TGF-b (44). Serum-free CM from
stimulated macrophages was prepared and assayed for
TGF-b activity using the MLEC-luciferase assay. Levels of
mature TGF-b present in CM from cultures treated with
Ab 39, anti-450, or anti-849 IgG were similar to those
present in anti–TGF-b IgG containing CM harvested from
untreated cultures (Fig. 9 C). Like cocultures, stimulated
macrophages were unaffected by anti-1065 IgG with re-
spect to their ability to produce mature TGF-b (Fig. 9 C).
Assays of heat-activated CM from untreated or antibody-
treated stimulated macrophages revealed that all cultures
generated similar levels of total TGF-b (data not shown).
Results obtained using the MLEC-luciferase assay could
not be confirmed using the wound migration assay be-
cause the wound migration assay was unresponsive to
TGF-b  present in CM from stimulated macrophages. Ad-
dition of either recombinant TGF-b1 or neutralizing anti–
TGF-b IgG to CM from stimulated macrophages did not
affect the migration of endothelial cells (data not shown).
This may be due to the presence of migration stimulatory
factors in macrophage CM (2). Nevertheless, anti-450 or
anti-849 IgG blocked TGF-b generation by stimulated
macrophages as determined by the MLEC-luciferase as-
say, suggesting that these antibody effects on large latent
complex activation were not specific to cocultures of BAE
and BSM cells and that the role of LTBP-1 in activation
involves interactions with its amino- and carboxyl-termi-
nal regions.
Figure 9. Effect of antibodies to LTBP-1 on latent TGF-b activa-
tion by cocultures of BAE and BSM cells, and stimulated mac-
rophages. (A) The MLEC-luciferase assay was used to detect
TGF-b activity generated by cocultures of BAE and BSM cells.
Serum-free CM harvested from either untreated cultures or cul-
tures treated with 10 mg/ml Ab 39 IgG, 50 mg/ml nonimmune
IgG, or 50 mg/ml of affinity-purified anti-450, anti-1065, or anti-
849 IgG were assayed using the MLEC-luciferase assay. To verify
that luciferase production was TGF-b–dependent, 20 mg/ml neu-
tralizing anti–TGF-b IgG was added to CM from untreated cul-
tures. Data presented are from one out of four experiments yield-
ing similar results. (B) The wound migration assay was used to
detect TGF-b activity generated by cocultures of BAE and BSM
cells. Serum-free CM harvested from untreated cocultures or co-
cultures treated with the same antibodies as in A were assayed
for TGF-b activity using the wound migration assay described in
Materials and Methods. Control (100%) is the migration ob-
served in wounded BAE cultures treated with media from homo-
typic BAE and BSM cells mixed 4:1. These data are presented as
the percentage of migration observed in wounded cultures
treated with control media. Data are representative of four ex-
periments yielding similar results. (C) The MLEC-luciferase as-
say was used to detect TGF-b activity generated by stimulated
macrophages. Serum-free CM from either untreated or antibody-
treated cultures of LPS-stimulated thioglycollate-elicited perito-
neal macrophages were harvested and assayed. Antibody treat-
ments were as in A and B. Data presented are from one out of
three experiments yielding similar results.The Journal of Cell Biology, Volume 136, 1997 1160
Discussion
The reactants involved in the activation of latent TGF-b
by cocultures of endothelial and smooth muscle cells, ret-
inoid-treated BAE cells, and stimulated macrophages in-
clude plasmin, cation-independent mannose 6-phosphate/
insulin-like growth factor type II receptor, tissue trans-
glutaminase, and LTBP-1 (27). Interactions between the
reactants involved in the activation of latent TGF-b have not
been characterized in cell-free systems, with the exception
that plasmin can cleave LAP, destabilizing noncovalent
interactions between LAP and TGF-b, and that recombi-
nant small latent complex binds to the cell surface cation-
independent mannose 6-phosphate/insulin-like growth fac-
tor type II receptor via mannose 6-phosphate residues
present on LAP (16, 35, 36). In this article, we have identi-
fied and characterized interactions between two reactants,
LTBP-1 and tissue transglutaminase, that may be involved
in latent TGF-b activation by cocultures of BAE and BSM
cells as well as LPS-stimulated thioglycollate-elicited mac-
rophages (31, 44, 54). These interactions include an en-
zyme–substrate relationship between transglutaminase and
LTBP-1 and transglutaminase-dependent anchoring of large
latent complex to the ECM. In addition, a second func-
tional domain of LTBP-1 involved in latent TGF-b activa-
tion was identified.
Matrix incorporation of LTBP-1 or large latent complex
(reported by others and reproduced by us) appears to oc-
cur through transglutaminase-dependent cross-linking of
LTBP-1 and matrix protein(s) (60). We observed that both
large latent complex and LTBP-1 are substrates for trans-
glutaminase, the LTBP-1 of large latent complex contains
residues involved in cross-linking large latent complex, and
the inhibition of transglutaminase severely attenuates the
incorporation of LTBP-1 into the matrix. Transglutami-
nase-reactive sites of LTBP-1S appear to be located within
residues 294 and 441 of the amino terminus, as an LTBP-1S
mutant truncated at its amino terminus by 441 amino acids
was not cross-linked to the matrix, whereas a 293–amino
acid truncated LTBP-1S retained its matrix association.
Transglutaminase is more selective for glutamine resi-
dues than acyl acceptor sites (25). A consensus sequence
for glutamine residues that serve as amine acceptor sites in
transglutaminase-catalyzed cross-linking has not been de-
scribed. However, LTBP-1S shares some structural fea-
tures present in other transglutaminase substrates. Se-
quence analysis of reactive glutamine residues reveals that
they are exposed in loop structures, as the glutamines tend
to be surrounded by positively or negatively charged amino
acids (4). In 60% of the substrates, glutamine residues are
located at the amino or carboxyl terminus. From sequence
alignment analysis of human LTBP-1S and LTBP-2, rat
LTBP-1 and murine LTBP-3 (28, 43, 45, 64), glutamine-
374 and a positively flanking amino acid within the second
cysteine-rich repeat of LTBP-1S is conserved among all
LTBPs, suggesting that it may be a transglutaminase reac-
tive site. Glutamine-374 is present in DN293 LTBP-1S,
which was incorporated into ECM but is absent in DN441
LTBP-1S, which appeared not to be cross-linked to ECM.
Identification of the transglutaminase-reactive glutamine(s)
is a current subject of investigation using biochemical and
molecular approaches.
The matrix protein(s) to which LTBP-1 is cross-linked
has not been identified. However, LTBP-1 has been de-
scribed to colocalize with fibronectin (Taipale, J., J. Sahar-
inen, K. Hedman, and J. Keski-Oja. 1994. Mol. Biol. Cell.
5[Suppl.]:311a) and with collagen-free fibrillar structures
generated by fetal rat calvarial cells (13). LTBP-2 appears
to closely associate with elastin-associated microfibrils (22).
Thus, fibronectin and proteins of elastic fibers, such as mi-
crofibril-associated glycoprotein, are candidate proteins,
as they all contain residues susceptible to transglutami-
nase-catalyzed isopeptide bond formation (10, 37).
In addition to localizing the transglutaminase reactivity
of LTBP-1S to amino-terminal residues 294–441, LTBP-1S
domains participating in latent TGF-b activation were iden-
tified. Both the amino and carboxyl regions of LTBP-1S
appear to be involved in protein interactions required for
activation as antibodies to these two domains abrogated
TGF-b generation by cocultures of BAE and BSM cells as
well as by LPS-stimulated thioglycollate-elicited macro-
phages. Previously, we reported that protein A–purified anti-
450 IgG (the antibody to the amino terminus of LTBP-1S)
did not affect activation of large latent complex by stimu-
lated macrophages (44). This discrepancy results from the
fact that in the earlier work total IgG was used, whereas in
the experiments reported here affinity-purified IgG was
tested. Based upon the concentration of affinity-purified
anti-450 IgG required to inhibit activation of large latent
complex, the amount of IgG used previously would have
been insufficient to observe an effect. Anti-450 IgG also
inhibited matrix association of LTBP-1 and large latent
complex, suggesting that the role of the amino terminus in
latent TGF-b activation may be to mediate the incorpora-
tion of large latent complex into the matrix.
We have demonstrated that the carboxyl-terminal re-
gion of LTBP-1 is required for large latent complex activa-
tion, as antibodies to this region blocked TGF-b genera-
tion (44). The carboxyl-terminal sequence of LTBP-1 does
not appear to contain sites involved in covalently attaching
LTBP-1 to the ECM, as addition of these antibodies to
cultures did not affect the matrix content of LTBP-1. This
region does contain a putative protease-sensitive site at
residue 1257 located after the third cysteine-rich repeat
(28, 49, 60). Cleavage at this site might facilitate activation
of soluble forms of large latent complex.
Matrix incorporation of large latent complex may create
a concentrated pool of large latent complex. Others have
proposed that segregating pools of latent TGF-b may be
important in regulating the conversion of large latent com-
plex to mature TGF-b at specific sites (23). Alternatively,
we speculate that soluble large latent complex may be re-
sistant to plasmin activation. It has been demonstrated
that activation of latent TGF-b in fibroblast CM by plas-
min requires nonphysiological levels of plasmin (35). We
also find that recombinant large latent complex is not
readily activated by plasmin in solution (data not shown).
Therefore, cross-linking to the matrix may sequester large
latent complex that is not readily activated, and subse-
quent release from the matrix by proteolysis (60) could
generate a modified complex susceptible to plasmin acti-
vation.
We propose that the activation of large latent complex,
to release, TGF-b occurs by the sequence of reactions il-Nunes et al. Latent Transforming Growth Factor-b Activation 1161
lustrated in Fig. 10. Cross-linking large latent complex to
the ECM is an early step in activation of large latent com-
plex. From our antibody inhibition studies on latent TGF-b
activation, both the amino and carboxyl domains of
LTBP-1 are involved in protein interactions necessary for
activation. The role of the amino terminus of LTBP-1S ap-
pears to be in the cross-linking of large latent complex to
the matrix, as we observed that the amino terminus con-
tains transglutaminase reactive sites and transglutaminase
activity is required for activation (31). We propose that
matrix-bound large latent complex is released by cleaving
LTBP-1S at a potential tribasic protease site (arginine-
415) on the carboxyl side of the transglutaminase reactive
residue(s). This site has been proposed by Taipale et al. to
be plasmin sensitive (60). We hypothesize that the car-
boxyl domain of LTBP-1S is involved in forming noncova-
lent interactions, perhaps with matrix, as antibodies to this
domain did not interfere with the cross-linking to the ma-
trix but did block TGF-b generation. An additional cleav-
age of LTBP-1S at the carboxyl terminus (residue 1257) as
proposed by Taipale et al. (60) would release a complex
with an LTBP-1 molecule containing only its core EGF-
like repeats plus cysteine-rich repeats 3–4 bound to small
latent complex. This proteolytic processing of large latent
complex may be required for subsequent activation steps,
such as binding to cell surface mannose 6-phosphate/insu-
lin-like growth factor type II receptors (16, 32). We specu-
late that cross-linking to the matrix occurs before targeting
to the cell surface mannose 6-phosphate/insulin-like factor
type II receptor, as the addition of excess mannose 6-phos-
phate does not interfere with the matrix association of
LTBP-1 or large latent complex (data not shown) but ab-
rogates TGF-b generation (16). Once on the cell surface,
fragmented latent complex is susceptible to plasmin-depen-
dent activation by proteolytic cleavage of LAP (27, 36).
The TGF-b released then binds to its receptor.
This model suggests several testable questions. These in-
clude the potential significance of the putative plasmin
cleavage sites in LTBP-1S, the availability of the mannose
6-phosphate residues of LAP in the complex, and the loca-
tion of plasmin-sensitive sites of LAP. It is also unknown
whether large latent complexes that differ in their LTBP
isoforms are activated by a similar mechanism. Answers to
these questions can be approached by altering specific res-
idues in the components of large latent complex and moni-
toring rates of large latent complex activation.
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